Natural killer (NK) cell-based immunotherapies are attracting increasing interest in the field
of cancer treatment. Early clinical trials have shown promising outcomes, alongside …

Genetically engineered immune cells expressing chimeric antigen receptors (CARs) have
emerged as a new game changer in cancer immunotherapy. The utility of CAR T cell therapy …

The immune-cell origin of hematologic malignancies provides a unique avenue for the
understanding of both the mechanisms of immune responsiveness and immune escape …

Advancements in chimeric antigen receptor engineered T-cell (CAR-T) therapy have
revolutionized treatment for several cancer types over the past decade. Despite this success …

Natural killer (NK) cells, a unique component of the innate immune system, are inherent
killers of stressed and transformed cells. Based on their potent capacity to kill cancer cells …

Adoptive cellular therapy using chimeric antigen receptor (CAR) T cells has led to a
paradigm shift in the treatment of various hematologic malignancies. However, the broad …

Chimeric antigen receptor (CAR)-engineered T (CAR-T) cells have obtained prominent
achievement in the clinical immunotherapy of hematological malignant tumors, leading to a …

Simple Summary New approaches in adoptive immunotherapy using chimeric antigen
receptor (CAR)-modified cells have been developing very quickly in recent years, entering …

Chimeric antigen receptor T (CAR-T) cell therapy has revolutionized the treatment of
hematological malignancies, demonstrably improving patient outcomes and prognosis …

Chimeric antigen receptor (CAR) T cell therapy has been a great success in CD19+
hematological diseases. Natural killer (NK) CAR cells offer an alternative to CAR T cells with …